Didanosine Conference Data

Medical Advocates
Didanosine (Videx)

Conference Citations

XVI International AIDS Conference
13th CROI
3rd IAS Conference
6th Int Wkshp on Clinical Pharmacology of HIV Therapy
12th CROI
XV International AIDS Conference
11th CROI
2nd IAS Conference
XIV International AIDS Conference

DDI Conference Main Page DDI Main Page Home Page

Last Update: March 29, 2015
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Perinatal Data are integrated with Perinatal Conference Data in the Perinatal Data Page
Pediatric Data are integrated with Pediatric Conference Data in the Pediatric Data Page

XVI International AIDS Conference

Stavudine or didanosine use, low-level transaminitis (LLT) and hepatic steatosis in a cohort of
HIV mono-infected subjects
Bongiovanni M., Smith C., Bhagani S., et al
Abstract
Bioequivalence of two different brands of didanosine after single dose administration in 30 healthy
volunteers
Mahler E., Monzón C., Fridman D., et al
Abstract

12th Conference on Retroviruses and
Opportunistic Infections

Didanosine and Lower Baseline Body Weight Are Associated with Declining Renal Function
among Patients Receiving Tenofovir
H Crane, R Harrington, S Van Rompaey, M Kitahata
Abstract
Didanosine Lowers Mitochondrial DNA Levels in Peripheral Blood Mononuclear Cells in
HIV-1-infected Children Receiving HAART
A Saitoh, T Fenton, C Alvero, et al
Abstract

3rd IAS Conference

Adherence and quality of life with a once-daily antiretroviral regimen with didanosine (ddI),
lamivudine (3TC) and efavirenz (EFV) in naïve patients. The VESD study.
Palacios R., del Arco A., Grana M., et al
Abstract

Prevalence of Polyneuropathy (PNP) in HIV Patients on HAART with DDI+3TC+EFV on a
Once-a-day regimen.
Villelabeitia K, Rivas P., Ibarra I., et al
Abstract
Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine (ddI), lamivudine
(3TC) and efavirenz (EFV) in naïve patients. The VESD study
Santos J., Palacios R., López M., et al
Abstract

Immunologic and Virologic Responses With Combination Didanosine/Tenofovir Compared to
Other Nucleoside Regimens
Furtek K., Crum N.F., Powell T, et al
Abstract

Effects of taking didanosine capsules (ddI-EC) with and without food on virological failure and
treatment discontinuation: The FOODDIe Study.
Lopez J., Moreno S., Jimenez-Oñate F., et al
Abstract

Efficacy and Safety of a QD Simplification Regimen with Didanosine plus Tenofovir plus Efavirenz –
Final results of the EFADITE Trial
Barrios A., Negredo E., Vilaro J., et al
Abstract

No significant interaction between TMC125 and didanosine (ddI) in healthy volunteers.
Scholler M., Hoetelmans R., Bollen S., et al
Abstract

Efficacy and safety of a QD regimen (didanosine, lamivudine and efavirenz) as initial therapy
in HIV-infected patients
Sanchez-Conde M., Asensi V., C Waiwaravuth, et al
Abstract

6th International Workshop on Clinical Pharmacology
of HIV Therapy

PDF POSTER
Atazanavir (ATV) enhances trough concentrations of Nelfinavir (NFV) and its M8 metabolite
in a treatment regimen without Ritonavir (RTV)
M Kurowski, et al
PDF Poster

12th Conference on Retroviruses and
Opportunistic Infections

Higher Risk of Hyperglycemia in Patients under Didanosine- and Tenofovir-
containing Regimens
T García-Benayas, A Barrios, M Sánchez-Conde, et al
Abstract
Prediction of Early HIV-1 RNA Reduction in the Jaguar Study Using Phenotypic
Susceptibility to Didanosine
M Bates , P Flandre, K Ryan, et al
Abstract
Pharmacokinetics of Didanosine Enteric Coated Capsules Co-administered with
Atazanavir or Atazanavir/Ritonavir
S Kaul , C Olszyk, P Ji, et al
Abstract
Stability of Didanosine and Stavudine Pediatric Oral Solutions and Kaletra Capsules
at Temperatures from 4°C to 55°C
S Lockman , P Ndase, D Holland
Abstract

XV International AIDS Conference

Body composition and metabolic changes in antiretroviral-naive HIV-infected patients randomized to
didanosine and stavudine (ddI+d4T) vs. abacavir and lamivudine (ABC+3TC)
JC Shlay, F Visnegarwala, G Bartsch, et al
Abstract

Virologic outcomes with didanosine-containing salvage therapy are not predicted by available
genotypic HIV-1 resistance interpretation rules but by selected reverse transcriptase mutations:
protective role of M184V
S Di Giambenedetto, A Antinori, A Cingolani, et al
Abstract

Efficacy and safety of didanosine (ddI) and tenofovir (TDF) combination as NRTI backbone of highly
active antiretroviral treatment (HAART). (24 wk preliminary results from Recover Study)
MJ Galindo Puerto, J López-Aldeguer, M Salavert, et al
Abstract

Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine
ddI) plus hydroxyurea
M López, V Soriano, S Lozano, et al
Abstract

Up-regulatory mechanisms compensate mitochondrial DNA depletion in asymptomatic individuals
receiving didanosine plus stavudine (ddI+d4T)
O Miro, S López, M Rodríguez, et al
Abstract
Safety and tolerability of didanosine combined with tenofovir DF in ambulatory HIV-1 infected adult
individuals
B Young, C Armon, R Baker, et al
Abstract

11th Conference on Retroviruses and Opportunistic
Infections

PDF POSTER
Potentially Preventive Effect of Didanosine against HIV Encephalopathy
I Poizot Martin, M P Milon, M P Drogoul, et al
PDF Poster Abstract

PDF POSTER
Unexpected CD4 Cell-count Decline in Patients Receiving Didanosine- and
Tenofovir-based Regimens Despite Undetectable Viral Load
E Negredo, J Moltó, D Burger, et al
PDF Poster Abstract

Poor Virologic Responses and Early Emergence of Resistance in Treatment
Naive, HIV-infected Patients Receiving a Once Daily Triple Nucleoside Regimen
of Didanosine, Lamivudine, and Tenofovir DF
J Jemsek, P Hutcherson, E Harper
Abstract

Safety and Efficacy of a QD Simplification Regimen
A Barrios, E Negredo, J Vilaró-Rodríguez, et al
Abstract

Didanosine Prevents HIV Protease Inhibitor-induced Atherosclerotic Lesion Formation
in LDL Receptor Null Mice
K Collard, R N Greenberg, T Guerin, E J Smart
Abstract

Comparison of Genotype and Phenotype as Predictors of Short-term Virologic |
Response to Didanosine in Nucleoside Analogue-experienced Patients
F Clavel, AG Marcelin, J Pavie, et al
Abstract

2nd IAS Conference on HIV and Pathogenesis

A PILOT STUDY OF SHORT CYCLE INTERMITTENT ARV THERAPY UTILIZING A ONCE PER
DAY REGIMEN OF DIDANOSINE, LAMIVUDINE AND EFAVIRENZ
M. Dybul, E. Nies-Kraske, R. Dewar, et al
Abstract

CLINICAL IMPACT OF THE M184V MUTATION AMONG HIGHLY ACTIVE ANTIRETROVIRAL
THERAPY (HAART) -EXPERIENCED PATIENTS ON DIDANOSINE (DDI)
M. Torok, S. Napravnik, R. McKaig, et al
Abstract

PANCREATIC TOXICITY ASSOCIATED WITH THE CO-ADMINISTRATION OF DIDANOSINE AND
TENOFOVIR
A. Milinkovic, G. Ravasi, J. Mallolas, et al
Abstract

XIV International AIDS Conference

Peripheral neuropathy in HIV-1 adult infected patients using Stavudine and Didanosine in a
combination therapy with Efavirenz
A Ndir, S Thiam, A Canestri, et al
Abstract
Switching from didanosine buffered tablets (Videx or Generic ddi) to enteric coated capsules
(Videx EC) in human immunodeficiency virus type-I infected patients controlled by highly active
antiretroviral therapy: preliminary report of patients that completed 12 weeks of follow-up
JC Cha Torea, I Casetti, A Casiro, et al
Abstract

Adherence and efficacy of HAART with bid or qd didanosine
B Roca, C Lapuebla, J Madero, et al
Abstract

Pharmacokinetics (pK) of didanosine (ddI) from encapsulated enteric coated bead formulation (EC)
vs chewable tablet formulation in patients (pts) on chronic methadone therapy
G Friedland, P Rainey, P Jatlow, et al
Abstract

Improved tolerability and adherence with enteric coated didanosine capsules (VidexEC) versus
buffered tablets (Videx)
SK Chuck, D Areff
Abstract

Adverse effects profile of didanosine + stavudine backbone antiretroviral therapy in naive hiv infected
patients
M Gomila, P Domingo, M A Sambeat, et al
Abstract
Acute pancreatitis associated with the concurrent use of valganciclovir and didanosine
PPF Pecora Fulco, RTH Higginson, RO Orenstein
Abstract

DDI Main Page Main New/Newsworthy Home Page

Didanosine
Conference Data